MLL-AF4 leukemia in humans has long been known to have a unique and distinctive biology with a lymphoid or mixed lineage phenotype, high incidence in infants and a poor prognosis. The overall goal of this completive renewal is to expand our studies of the last 20 years that are designed to understand the unique molecular and cellular pathobiology of MLL-AF4 leukemia. Emphasis will be on our novel MII-AF4 knock in murine model developed recently in the Kersey laboratory as a result of technical advances over the past four years. Knock in models of MLL fusion gene leukemia have the advantage of expression of the fusion gene under control of the physiologic promoter and haploinsufficiency of MLL as in human leukemia To our knowledge this is the first MLL-AF4 model demonstrating an expansion of the lymphoid compartment in vitro and in vivo and eventual leukemia. This is significant because human MLL-AF4 leukemia develops within the lymphoid compartment. In contrast MLL-AF9 results in myeloid compartment expansion and myeloid leukemia; Human MLL-AF9 leukemia is generally myeloid. These results are consistent with an active and instructive (rather than a passive) role for the MLL partner gene in determination of the eventual leukemia phenotype. In the next grant period our specific aims are directed at detailed mechanistic studies interrogating the major hematopoietic progenitor and stem cell populations to understand the cellular basis for this active and instructive role of the MLL fusion partner (AF4 or AF9) in this selective expansion The MLL-AF4 mice to date have developed leukemia only after 5 months and somewhat unexpectedly have been myelomonocytic rather than lymphoid in type. In collaboration with Dr. David Largaespada we will work to develop a fully penetrant model of MLL-AF4 initiated lymphoid leukemia. In these studies we will evaluate cooperating mutations including FLT3 and mutations induced by END or a novel MuLV retrovirus. The possible role of haploinsufficiency of AF4 in the development of MLL-AF4 lymphoid leukemia will be evaluated. Our preliminary data indicate that 51 HOX A cluster genes play a significant role as targets for MLL fusion genes. In this grant period we will conduct detailed studies of 51 HOX A cluster and MEIS1 genes in the progenitor and stem cell populations in both MLL-AF4 and MLL-AF9 mice. Consideration will be given to HOXA cluster, MEIS1 or MLL fusion genes as potential therapeutic targets. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA087053-06
Application #
7103581
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Mufson, R Allan
Project Start
2000-07-01
Project End
2010-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
6
Fiscal Year
2006
Total Cost
$273,182
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pathology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Bindels, Eric M J; Havermans, Marije; Lugthart, Sanne et al. (2012) EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 119:5838-49
Kumar, Ashish R; Yao, Qing; Li, Quanzhi et al. (2011) t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL. Leuk Res 35:305-9
Kumar, Ashish R; Sarver, Aaron L; Wu, Baolin et al. (2010) Meis1 maintains stemness signature in MLL-AF9 leukemia. Blood 115:3642-3
Kumar, Ashish R; Li, Quanzhi; Hudson, Wendy A et al. (2009) A role for MEIS1 in MLL-fusion gene leukemia. Blood 113:1756-8
Chen, Weili; Kumar, Ashish R; Hudson, Wendy A et al. (2008) Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 13:432-40
Yao, Qing; Weigel, Brenda; Kersey, John (2007) Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 13:1591-600
Chen, Weili; Li, Quanzhi; Hudson, Wendy A et al. (2006) A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 108:669-77
Yao, Q; Nishiuchi, R; Kitamura, T et al. (2005) Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia 19:1605-12
Yao, Qing; Nishiuchi, Ritsuo; Li, Quanzhi et al. (2003) FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 9:4483-93
Johnson, Jennifer J; Chen, Weili; Hudson, Wendy et al. (2003) Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. Blood 101:3229-35